HKSE - Delayed Quote HKD

CSPC Pharmaceutical Group Limited (1093.HK)

6.600 +0.080 (+1.23%)
At close: April 26 at 4:08 PM GMT+8
Currency in CNY All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
31,450,109.000
31,450,109.000
30,936,904.000
27,866,870.000
24,942,204.000
Cost of Revenue
9,273,423.000
9,273,423.000
8,680,490.000
6,731,776.000
6,256,882.000
Gross Profit
22,176,686.000
22,176,686.000
22,256,414.000
21,135,094.000
18,685,322.000
Operating Expense
15,160,675.000
15,160,675.000
15,496,781.000
14,885,836.000
12,628,654.000
Operating Income
7,016,011.000
7,016,011.000
6,759,633.000
6,249,258.000
6,056,668.000
Net Non Operating Interest Income Expense
-25,896.000
-25,896.000
-24,891.000
-7,664.000
-12,232.000
Pretax Income
7,389,372.000
7,389,372.000
7,582,261.000
6,847,096.000
6,391,023.000
Tax Provision
1,316,679.000
1,316,679.000
1,350,211.000
1,158,972.000
1,162,013.000
Net Income Common Stockholders
5,873,325.000
5,873,325.000
6,091,390.000
5,605,185.000
5,159,655.000
Diluted NI Available to Com Stockholders
5,873,325.000
5,873,325.000
6,091,390.000
5,605,185.000
5,159,655.000
Basic EPS
0.51
0.49
0.51
0.47
0.43
Diluted EPS
0.51
0.49
0.51
0.47
0.43
Basic Average Shares
11,887,658.014
11,872,021.000
11,917,204.000
11,953,486.000
11,954,570.000
Diluted Average Shares
11,891,331.894
11,873,031.000
11,918,523.000
11,953,839.000
11,955,537.000
Total Expenses
24,434,098.000
24,434,098.000
24,177,271.000
21,617,612.000
18,885,536.000
Net Income from Continuing & Discontinued Operation
5,873,325.000
5,873,325.000
6,091,390.000
5,605,185.000
5,159,655.000
Normalized Income
5,846,319.354
5,846,319.354
6,051,884.174
5,574,144.577
4,887,155.914
Interest Expense
25,896.000
25,896.000
24,891.000
7,664.000
12,232.000
Net Interest Income
-25,896.000
-25,896.000
-24,891.000
-7,664.000
-12,232.000
EBIT
7,415,268.000
7,415,268.000
7,607,152.000
6,854,760.000
6,403,255.000
EBITDA
8,532,758.000
8,532,758.000
8,655,091.000
7,720,231.000
7,212,062.000
Reconciled Cost of Revenue
9,273,423.000
9,273,423.000
8,680,490.000
6,731,776.000
6,256,882.000
Reconciled Depreciation
1,117,490.000
1,117,490.000
1,047,939.000
865,471.000
808,807.000
Net Income from Continuing Operation Net Minority Interest
5,873,325.000
5,873,325.000
6,091,390.000
5,605,185.000
5,159,655.000
Total Unusual Items Excluding Goodwill
32,861.000
32,861.000
48,065.000
37,365.000
333,055.000
Total Unusual Items
32,861.000
32,861.000
48,065.000
37,365.000
333,055.000
Normalized EBITDA
8,499,897.000
8,499,897.000
8,607,026.000
7,682,866.000
6,879,007.000
Tax Rate for Calcs
0.000
0.000
0.000
0.000
0.000
Tax Effect of Unusual Items
5,855.354
5,855.354
8,559.174
6,324.577
60,555.914
12/31/2020 - 5/13/2003

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

600276.SS Jiangsu Hengrui Medicine Co., Ltd.
45.61
+2.96%
 
1666.HK Tong Ren Tang Technologies Co. Ltd.
5.310
+7.71%
 
RHO6.SG Roche Holding AG
28.05
0.00%
 
RHHBF Roche Holding AG
255.60
-6.51%
 
ROG.SW Roche Holding AG
221.00
+1.01%
 
GSK.L GSK plc
1,653.00
+0.76%
 
RHHBY Roche Holding AG
30.25
+0.77%
 
AZN AstraZeneca PLC
75.17
+0.19%
 
NVS Novartis AG
97.44
-1.64%
 
BMY Bristol-Myers Squibb Company
44.85
+0.34%